Therapeutics and Clinical Risk Management (Feb 2020)

Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?

  • Kyriazoglou A,
  • Koutsoukos K,
  • Zagouri F,
  • Liontos M,
  • Dimitriadis E,
  • Tiniakos D,
  • Dimopoulos MA

Journal volume & issue
Vol. Volume 16
pp. 141 – 146

Abstract

Read online

Anastasios Kyriazoglou, 1 Konstantinos Koutsoukos, 1 Flora Zagouri, 1 Michalis Liontos, 1 Efthimios Dimitriadis, 2 Dina Tiniakos, 3, 4 Meletios Athanasios Dimopoulos 1 1Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece; 2Department of Genetics, Agios Savvas Hospital, Athens, Greece; 3Department of Pathology Aretaion Hospital, National & Kapodistrian University of Athens, Athens, Greece; 4Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UKCorrespondence: Anastasios Kyriazoglou Vasilisis Sofias 80, Athens 11528, GreeceTel +302132162545Fax +302132162511Email [email protected]: Epithelioid hemangioendothelioma (EHE) is a rare vascular malignant tumor with indolent course. Liver transplantation for local disease is the treatment of choice. In the metastatic setting there is no consensus regarding the appropriate systemic treatment. We present two cases of metastatic hepatic epithelioid hemangioendothelioma (hEHE) treated with the combination of Doxorubicin and Olaratumab. Both patients showed Stable Disease (SD) as a response, after the completion of six cycles of this combination therapy.Keywords: Olaratumab and Doxorubicin, metastatic hepatic epithelioid hemangioendothelioma, 1st line treatment

Keywords